Pneumonia

Phase III Trial for Tifacogin initiated

Published in TB and Outbreaks Week, June 15th, 2004

Chiron Corporation (CHIR) announced that it has initiated a phase III trial for tifacogin as a treatment for severe community-acquired pneumonia (severe CAP).

Severe CAP is defined as pneumonia contracted outside of a hospital setting that requires the patient's admission to an intensive-care unit. Tifacogin, developed by Chiron, is a recombinant form of tissue factor pathway inhibitor, or TFPI, a naturally occurring protein in the body.

"The mortality rate associated with severe CAP has remained constant for the past 50 years in spite of significant advances in antibiotic therapy. We believe that tifacogin has the potential to impact this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry